Quo vadis SALIX - 500 Beiträge pro Seite

[Oberkassel]

Mission

Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.

Company strategy

Provide treatment to people with gastrointestinal (GI) disorders

We are passionate about providing solutions to problems that affect millions of Americans every year. We strive to address unmet treatment needs for people with GI disorders.

In-license selective late-stage/marketed products

Our search and development efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal diseases that have an existing base of safety and efficacy data.

Sell products through a specialty sales force

Salix has a direct sales force to promote our products to healthcare providers in the United States responsible for treating gastrointestinal disease. We believe that our specialty sales force—and the high level of service we are able to provide—allows us to capitalize on the opportunity to build a franchise with the gastroenterology community.

Growth by leveraging our product development and product sales infrastructure

We will grow our business by adding new products to our portfolio. We intend to add new product opportunities by
•Expanding the indications for our current products
•In-licensing or acquiring new products
•Copromoting selected third-party products

http://www.salix.com/index.aspx

Gelistet: Nasdaq, Deutschland (Stuttgart, Frankfurt, Berlin)
Geringer Handel in Deutschland!


Marktkapitalisierung: 7,1 US§ Mrd
Land:USA
Typ:Namensaktie
Peer Group:Impax Labs, Teva Pharma, Actavis


Wettbewerber

GlaxoSmithKline
Bayer AG
Warner Chilcott

Kennzahlen
2013 2014 2015
Ergebnis / Aktie 2,78 EUR 4,80 EUR 5,53 EUR
Kurs-Gewinn-Verhältnis 23,92 17,51 15,20
Cash-Flow / Aktie 4,68 EUR 5,46 EUR 5,82 EUR
Kurs-Cash-Flow-Verhältnis 14,21 15,41 14,44
(Schätzungen 2014,2015)


Financial Highlights

Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Mar 31, 2014
Profitability
Profit Margin (ttm): 6.88%
Operating Margin (ttm): 25.35%
Management Effectiveness
Return on Assets (ttm): 5.27%
Return on Equity (ttm): 11.82%
Income Statement
Revenue (ttm): 1.12B
Revenue Per Share (ttm):17.90
Qtrly Revenue Growth (yoy):89.70%
Gross Profit (ttm):754.45M
EBITDA (ttm)6: 379.06M
Net Income Avl to Common (ttm): 76.72M
Diluted EPS (ttm): 1.18
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq):385.10M
Total Cash Per Share (mrq):6.07
Total Debt (mrq):2.83B
Total Debt/Equity (mrq):397.28
Current Ratio (mrq): 2.52
Book Value Per Share (mrq):11.23
Cash Flow Statement
Operating Cash Flow (ttm):14.30M
Levered Free Cash Flow (ttm):-115.19M

Aufschlüsselung

% of Shares Held by All Insider and 5% Owners:3%
% of Shares Held by Institutional & Mutual Fund Owners: 99%
% of Float Held by Institutional & Mutual Fund Owners:101%
Number of Institutions Holding Shares:254


Shareholder

Fidelity Management & Research Co.7,211,996 11.4%
Wellington Management Co. LLP 7,074,801 11.2%
BlackRock Fund Advisors 4,481,419 7.07%
The Vanguard Group, Inc. 4,120,577 6.50%
SSgA Funds Management, Inc. 1,898,409 2.99%
Visium Asset Management LP 1,764,566 2.78%
Columbia Management Investment Advisers LLC 1,679,239 2.65%
TimesSquare Capital Management LLC 1,671,050 2.64%
Viking Global Investors LP 1,551,766 2.45%
Federated Equity Management Company of Pennsylvania 1,346,972 2.12%


Indexzugehörigkeit

NASDAQ BIOTECHNOLOGY INDEX
NASDAQ COMPOSITE INDEX
NASDAQ GLOBAL SELECT MARKET COMPOSITE
S&P 400
S&P MIDCAP 400 INDEX (PRICE)
S&PSMALLCAP600INDEX

Fonds

Adamant Global Healthcare Index Fonds I CHF
Lacuna - Adamant Global Healthcare I
ESPA STOCK BIOTEC TC

Wichtige Termine in 2014:

06/18/14 Wells Fargo Securities Healthcare Conference
06/25/14 JMP Health Care Conference
07/09/14 Investor Day
08/11/14 Interim 2014 Earnings Release (Projected)

Warum jetzt Salix ?

Da die Branche in den letzten Wochen korrigiert hat und Salix viele Medikamente in Phase 3 hat und mögliche Zulassungen erhalten wird, halte ich es für spannend den Wert sich näher anzuschauen.
Sehr gutes Management,erfahrene und solide Statements. Ein stetiger Aufwärtstrend seit vielen Jahren und das Zahlenwerk von SALIX.

Chartechnik:CC

Unser Pivot-Punkt liegt bei 106.5.
Unsere Meinung: solange die Unterstützung bei 106.5 hält, sind 121.6 das Ziel
Alternatives Szenario: ein Fall unter 106.5 würde einen weiteren Rückgang auf 99.2 auslösen
Analyse: der RSI liegt über der Neutralitätszone von 50. Der MACD liegt unter der Signallinie und ist positiv. Die Aktie könnte kurzfristig wieder zurückgehen. Es wird darauf hingewiesen, dass die Volumina seit einigen Tagen fallen.

Gleitende Durchschnitte

38 Tage 81,6695 27,13%
100 Tage 78,7524 29,74%
200 Tage 68,4269 38,95%



Oberkassler

[Oberkassel]

Salix Pharmaceuticals Price Target Raised to $130.00 at Stifel (SLXP)

http://www.wkrb13.com/markets/322594/salix-pharmaceuticals-p…

Heuter schöner Sprung nach oben.

Oberkassler